LMNGF News and Press, BioVaxys Technology From 12/10/20

Vancouver, British Columbia--(Newsfile Corp. - December 10, 2020) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ( "BioVaxys" or "the Company") is pleased to announce that its submission of Form 211 to FINRA has been cleared and the Company's shares now qualify for trading in the United S...

Titer Analysis Confirms 100% Efficacy at All Higher Dose Levels in Murine Mouse Study; Preclinical Data Supports Expansion of Vaccine Platform Across Range of Viral Diseases Vancouver, British Columbia--(Newsfile Corp. - November 30, 2020) - BioVaxys Technology Corp. ( CSE: BIOV) (FSE: 5LB)...

Vancouver, British Columbia--(Newsfile Corp. - November 11, 2020) - BioVaxys Technology Corp. ( CSE: BIOV) (FSE: 5LB) ( "BioVaxys") is pleased to announce that results from its preclinical animal study (also known as the "murine model study") of BVX-0320, its Covid-19 vaccine candidate, show t...

Vancouver, British Columbia--(Newsfile Corp. - November 9, 2020) - BioVaxys Technology Corp. ( CSE: BIOV) (FSE: 5LB) ( " BioVaxys " or the " Company ") is pleased to announce that it has engaged Encounter Technology Limited (" Encounter "), a company controlled by one of its directors, Mr. Dav...

Vancouver, British Columbia--(Newsfile Corp. - November 2, 2020) -   BioVaxys Technology Corp. (CSE: BIOV) ("BioVaxys" or "the Company"), a world leader in haptenized protein vaccine research and development, announced today that it has filed a Provisional Patent Application with the U.S...

BioVaxys ([[LMNGF]]) has entered into a research agreement with The Ohio State University, for development of its preclinical SARS-CoV-2 vaccine candidate, BVX-0320.Under the research collaboration, the company will evaluate the neutralizing antibodies generated against live SA...

Vancouver, British Columbia--(Newsfile Corp. - October 26, 2020) - BioVaxys Technology Corp. ( CSE: BIOV ), is pleased to announce that it has entered into a research collaboration with The Ohio State University ("OSU") for BioVaxys' SARS-CoV-2 vaccine candidate. OSU is a leading global a...

Vancouver, British Columbia--(Newsfile Corp. - October 21, 2020) - BioVaxys Technology Corp. (CSE: BIOV) (formerly Lions Bay Mining Corp.) (" BioVaxys " or the " Company ") is pleased to announce that David Wang and Darren Hermiston have been appointed as directors of the Company. Mr. Hermisto...

BioVaxys Technology ([[LMNGF]]) has reported interim data from preclinical clinical studies of its SARS-CoV-2 vaccine candidate, BXV-0320.The study showed that after five weeks of BVX-0320 in the murine animal model, no side effects were observed.The company anticipates taking ...

Vancouver, British Columbia--(Newsfile Corp. - October 14, 2020) - BioVaxys Technology Corp. ( CSE: BIOV) ( "BioVaxys") is pleased to announce that interim results from its ongoing preclinical animal study (also known as a "murine model study") of BXV-0320, its SARS-CoV-2 vaccine candidate,...